News
Savient resubmits application for gout drug
46 minutes ago
Savient Pharmaceuticals Inc. said Monday that it resubmitted an application to have its gout drug approved by the Food and Drug Administration.Krystexxa, or pegloticase, is meant to treat gout in patients who have already tried other drugs.Paul Hamelin, president of Savient, said the latest...
Myriad, Javelin set April 22 for vote on buyout
46 minutes ago
Javelin Pharmaceuticals Inc. said Monday it has set April 22 as the date for its shareholders to vote on a proposed buyout by Myriad Pharmaceuticals Inc.Myriad's board also set an April 22 date for its shareholders to vote on the deal.On Dec. 18, Myriad Pharmaceuticals Inc., based in Salt Lake...
Driving retirement for seniors
1 hour ago
(Canadian Medical Association Journal) Public safety should win against personal choice especially when it comes to elderly seniors who shouldn't drive, states an editorial in CMAJ.
Inappropriate uses of frozen plasma
1 hour ago
(Canadian Medical Association Journal) Large amounts of frozen plasma are being used inappropriately, states a commentary in CMAJ.
Impax challenges patent on Abbott's Trilipix
1 hour ago
Impax Laboratories Inc. said Monday it is challenging the patent on Abbott Laboratories' cholesterol drug Trilipix, and plans to bring its own version to market.Impax is looking to sell a generic version of Trilipix in 54 milligram and 135 milligram capsules. Abbott and Fournier Laboratories...
BioSante cancer vaccine gets 'orphan drug' status
2 hours ago
BioSante Pharmaceuticals has received orphan drug status for its potential pancreatic cancer treatment, the company said Monday.The company said the Food and Drug Administration designation applied to its GVAX Pancreas Vaccine, which is undergoing clinical trials with other anticancer agents...
Why do sexually experienced girls resume sexual activity after abstinence?
3 hours ago
(Indiana University School of Medicine) An Indiana University School of Medicine study provides a better understanding of why sexually experienced girls resume sexual activity after periods of abstinence, information key to dealing with sexually transmitted diseases and pregnancy...
OSI board rejects Astellas' $3.5 billion offer
3 hours ago
OSI Pharmaceuticals on Monday asked its shareholders to reject a $3.5 billion takeover bid from Astellas Pharma Inc.On March 2, Astellas made the $52 per share tender offer, a 40 percent per-share premium at the time. The Japanese company also filed a lawsuit in Delaware to prevent OSI from...